Zoledronic acid (ZOL) is an intravenous bisphosphonate that is given once yearly for the treatment of osteoporosis via a medically supervised 15-minute infusion. Bisphosphonates are the primary treatment options for osteoporosis. Bisphosphonates specifically act on bone cells (osteoclasts) to inhibit bone resorption and turnover activity and reduce progressive bone loss and risk for fracture.
Dossier Available
Zoledronic acid – 4 mg/100 mL, 4 mg/5 ml, 5 mg/100 mL solution for infusion (glass vial)